Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy

References

• Weingarten MD, Lockwood AH, Hwo S-Y, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA. 1975;72:1858–62.
   PubMed Web of Science ®Google Scholar
• Kosik KS, Finch EA. MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum. J Neurosci. 1987;7:3142–53.
   PubMed Web of Science ®Google Scholar
• Avila J, Lucas JJ, Pérez M, Hernández F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84:361–84.
   PubMed Web of Science ®Google Scholar
• Compston A, Cole A. Multiple sclerosis. Lancet. 2002;359:1221–31.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Battaglini M, Smith S. Measuring brain atrophy in multiple sclerosis. J Neuroimaging. 2007;17:10S–5S.
   PubMed Web of Science ®Google Scholar
• Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol. 2000;43:228–32.
   PubMed Web of Science ®Google Scholar
• Terzi M, Birinci A, Çetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand. 2007;115:325–30.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Maier M, Arda S, Claus A, Süssmuth SD, Kassubek J, Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler. 2005;11:261–5.
   PubMed Web of Science ®Google Scholar
• Guimarães J, Cardoso MJ, Sá MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler. 2006;12:354–6.
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez FJ, Zurdo JM, Hernanz A, Medica-Acebrón S, de Bustos F, Barcenilla B, Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand. 2002;106:351–4.
   PubMed Web of Science ®Google Scholar
• Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005;64:1144–51.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.
   PubMed Web of Science ®Google Scholar
• Pachner AR, Steiner I. The multiple sclerosis severity score (MSSS) predicts disease severity over time. J Neurol Sci. 2009;278:66–70.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–7.
   PubMed Web of Science ®Google Scholar
• Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008;7:615–25.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol. 2011;69:292–302.
   PubMed Web of Science ®Google Scholar
• Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci. 2003;21:79–96.
   PubMed Web of Science ®Google Scholar
• Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001;310:173–86.
   PubMed Web of Science ®Google Scholar
• Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund L-O. Cerebrospinal fluid tau level increases with age in healthy individuals. Dement Geriatr Cogn Disord. 2001;12:127–32.
   PubMed Web of Science ®Google Scholar
• Sjögren M, Vanderstichele H, Ågren H, Zachrisson O, Edsbagge M, Wikkelsø C, Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem. 2001;47:1776–81.
   PubMed Web of Science ®Google Scholar
• Hesse C, Rosengren L, Adreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Transient increase in total-tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187–90.
   PubMed Web of Science ®Google Scholar
• Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M, Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur Neurol. 2002;47:45–51.
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale G, C-tau biomarker of neuronal damage in severe brain injury patients: association with elevated intracranial pressure and clinical outcome. Brain Res. 2002;947:131–9.
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem. 1999;72:741–50.
   PubMed Web of Science ®Google Scholar
• Süssmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett. 2001;300:95–8.
   PubMed Web of Science ®Google Scholar
• Wang GR, Gao C, Shi Q, Zhou W, Chen JM, Dong CF, Elevated levels of tau protein in cerebrospinal fluid of patients with probable Creutzfeldt-Jakob disease. Am J Med Sci. 2010;340:291–5.
   PubMed Web of Science ®Google Scholar
• Skinningsrud A, Stenset V, Gundersen AS, Fladby T. Cerebrospinal fluid markers in Creutzfeldt-Jakob disease. Cerebrospinal Fluid Res. 2008;5:14.
   PubMedGoogle Scholar
• Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS ONE. 2009;4:e6294.
   Web of Science ®Google Scholar
• Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729–34.
   PubMed Web of Science ®Google Scholar
• Solé-Padullés C, Lladó A, Bartrés-Faz D, Fortea J, Sánchez-Valle R, Bosch B, Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psych Res. 2011;192:140–6.
   PubMed Web of Science ®Google Scholar
• Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Phospho-tau/total-tau in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003;8:343–7.
   PubMed Web of Science ®Google Scholar
• Stadelman C. Multiple sclerosis as neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol. 2011;24:224–9.
   PubMed Web of Science ®Google Scholar
• Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 2011;122:155–70.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L. Multiple Sclerosis Collaborative Research Group. Use of brain parenchymal fraction measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53:1698–704.
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, Chiarini P, Absolute quantification of brain metabolites by proton magnetic spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain. 1999;122:513–21.
   PubMed Web of Science ®Google Scholar
• Tourbach A, Stievenart JL, Gout O, Fontaine B, Liblau R, Lubetzki C, Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology. 1999;53:1091–7.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868–76.
   PubMed Web of Science ®Google Scholar
• Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176–83.
   PubMed Web of Science ®Google Scholar
• Dal Bianco A, Bradl M, Frisher J, Kutzelnigg A, Jellinger K, Lassmann H. Multiple sclerosis and Alzheimer disease. Ann Neurol. 2008;63:174–83.
   PubMed Web of Science ®Google Scholar
• Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, A longitudinal study of T1 hypointense lesions in relapsing MS. MSCRG trial of interferon β-1a. Neurology. 2000;55:185–92.
   PubMed Web of Science ®Google Scholar
• Li BS, Regal J, Soher BJ, Mannon LJ, Grossman RI, Gonen O. Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2003;24:68–74.
   PubMed Web of Science ®Google Scholar
• Tam RC, Traboulsee A, Riddehough A, Sheikhzadeh F, Li DK. The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis. Mult Scler. 2011;17:949–57.
   PubMed Web of Science ®Google Scholar
• Meier DS, Guttmann CR. MRI time series modeling of MS lesion development. Neuroimage. 2006;32:531–7.
   PubMed Web of Science ®Google Scholar
• Mori F, Rossi S, Sancesario G, Codecà C, Mataluni G, Monteleone F, Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis. Neuropsychopharmacology. 2011;36:559–68.
   PubMed Web of Science ®Google Scholar